View Presentation Slides - PCSS-O

More documents

Recommendations

Info

Brief pharmacology overview: partial opioid agonists μ opioid receptor μ receptor partial agonist • Partial agonist binding activates the μ opioid receptor at lower levels • Is less reinforcing • Is a less abused opioid type • Blocks opioid agonist (and antagonist) binding • Partial agonists include: Buprenorphine
Brief pharmacology overview: opioid receptor antagonists μ opioid receptor μ receptor antagonist • Antagonist binding to the μ opioid receptor occupies without activating • Is not reinforcing • Blocks abused opioid agonist binding • Antagonists include: Naloxone and Naltrexone
Page 1 and 2: Patricia Pade, MD University of Col
Page 3 and 4: Objectives • To provide a brief o
Page 5 and 6: Chronic Pain • 116 million people
Page 7 and 8: Opioid Use • Use of opioids has i
Page 9 and 10: Fatal Drug Poisoning • Between 19
Page 11 and 12: Opioid Pharmacology: How do these M
Page 13 and 14: • Tolerance: Repeated Dosing: Opi
Page 15: Brief pharmacology overview: full o
Page 19 and 20: The Use of Buprenorphine/Naloxone t
Page 21 and 22: The Problem for Veterans
Page 23 and 24: Improvement Change: Creation of Co-
Page 25 and 26: Patient population • Referrals fr
Page 27 and 28: Initial Evaluation A. PAIN Detailed
Page 29 and 30: Buprenorphine induction process •
Page 31 and 32: Study participants Participant Data
Page 33 and 34: Months Average duration of opioid u
Page 35 and 36: Number Number Number 60 40 Co-morbi
Page 37 and 38: Adjuvant Medications Na and Interve
Page 39 and 40: Ongoing monitoring for compliance
Page 41 and 42: 93/143 patients remained in treatme
Page 43 and 44: Conclusions 11. Patients with co-oc
Page 45 and 46: Office Based Opioid Treatment: Bupr
Page 47: References 1. Institute of Medicine

View Presentation Slides - PCSS-O

Create successful ePaper yourself

Delete template?

Save as template?